Prevalence of postprandial hyperglycaemia in basal insulin-treated patients with type 2 diabetes mellitus with controlled fasting glycaemia and elevated glycosylated haemoglobin

Diabetology & Metabolic Syndrome
Francisco J TinahonesRicardo Gómez-Huelgas

Abstract

To study the prevalence of postprandial hyperglycaemia (PPH) in type 2 diabetes mellitus (T2DM) patients treated with basal insulin, having fasting glucose < 130 mg/dL but HbA1c > 7.0% (53 mmol/mol). This was an observational prospective multicentric study conducted in Spain. During 2 weeks, patients recorded a 6-point self-measured blood glucose profile (before and 2 h after eating) every 2 days. PPH was defined according to IDF and ADA guidelines (> 160 and > 180 mg/dL, respectively). We included 98 patients (males: 56.1%; mean age: 64.3 ± 10.4 years) who were treated with basal insulin for at least 1 year at stable doses in the last 2 months, 88.8% of them received concomitant oral antidiabetic drugs. Overall, 95.7% (95% CI 91.6-99.8) and 93.5% (95% CI 88.6-98.5) of patients showed ≥ 1 episode of PPH according to IDF and ADA criteria respectively. PPH was more frequently observed after lunch and dinner. The proportion of patients with ≥ 40% readings in range of PPH was 59.1% (95% CI 49.1-69.1) and 40.9% (95% CI 30.9-50.9), according to IDF and ADA criteria, respectively. PPH is very common and should be considered a priority target in basal insulin-treated T2DM patients with elevated HbA1c despite controlled fasting glucose.

References

Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Feb 15, 2001·Archives of Internal Medicine·UNKNOWN DECODE Study Group, the European Diabetes Epidemiology Group.
Sep 6, 2005·Biochemical and Biophysical Research Communications·Toshihiko ShiraiwaYoshimitsu Yamasaki
Mar 8, 2006·Clinical Therapeutics·Lawrence A LeiterUNKNOWN International Prandial Glucose Regulation Study Group
Jun 9, 2009·Diabetes Care·UNKNOWN International Expert Committee
Sep 24, 2010·International Journal of Clinical Practice·A Ceriello
Nov 9, 2011·Nature Reviews. Endocrinology·Lei ChenPaul Z Zimmet
Mar 14, 2013·Diabetes Research and Clinical Practice·UNKNOWN International Diabetes Federation Guideline Development Group
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Sep 27, 2014·Diabetes/metabolism Research and Reviews·Charles ShaeferMatthew Riddle
Dec 30, 2014·Diabetes Care·UNKNOWN American Diabetes Association
Feb 17, 2015·World Journal of Diabetes·Klaus-Dieter KohnertEckhard Salzsieder
Jun 30, 2015·Diabetes Research and Clinical Practice· Idf Diabetes Atlas Group

❮ Previous
Next ❯

Citations

Jun 18, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Laith N Al-EitanMansour A Alghamdi

❮ Previous
Next ❯

Software Mentioned

SAS
GLESMO

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.